Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation

Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis

(2017) Fangqiang Wei et al.   International Journal of Clinical Oncology

Dosing to rash? – The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash

(2016) Michael Steffens et al.   EUROPEAN JOURNAL OF CANCER

Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood–Brain Barrier: A PET Study on Nonhuman Primates

(2016) Nicolas Tournier et al.   JOURNAL OF NUCLEAR MEDICINE

Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors

(2015) Tomohiro Terada et al.   PHARMACOLOGY & THERAPEUTICS

Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies

(2014) Nicolas Widmer et al.   EUROPEAN JOURNAL OF CANCER

Association betweenEGFRgene polymorphisms, skin rash and response to anti-EGFR therapy in metastatic colorectal cancer patients

(2014) Ane Jaka et al.   EXPERIMENTAL DERMATOLOGY

The evolving genomic classification of lung cancer

(2013) David S Shames et al.   JOURNAL OF PATHOLOGY

Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies

(2012) Bo Gao et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain

(2011) M. Jamal-Hanjani et al.   CLINICAL CANCER RESEARCH

Population Analysis of Erlotinib in Adults and Children Reveals Pharmacokinetic Characteristics as the Main Factor Explaining Tolerance Particularities in Children

(2011) M. White-Koning et al.   CLINICAL CANCER RESEARCH

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Moving towards dose individualization of tyrosine kinase inhibitors

(2010) Heinz-Josef Klümpen et al.   CANCER TREATMENT REVIEWS

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals

(2008) Jian-quan Zhu et al.   CANCER LETTERS